يغطي هذا البروتوكول مرضى مرض الانسداد الرئوي المزمن المصنَّفين بوصفهم عالي الخطورة والذين لديهم نمط ظاهري غير يوزيني في الدم — نمط محدد يوجّه مساراً علاجياً مختلفاً.
DOI: 10.3390/jcm13020303
If any of these requirements are exceeded, they will be classified as "high risk".
On the other hand, patients at high risk should be differentiated by phenotype: in the case of a non-acute and non-eosinophilic patient, treatment should be initiated with LABA + LAMA, and in the case of an eosinophilic patient, treatment should be initiated with IC + LABA (Figure 1).
High-risk patients on dual bronchodilation may need triple therapy (LABA + LAMA + CI) in a single inhaler (Figure 1).
If IC is necessary, it is recommended to combine it with LABA + LAMA rather than with LABA alone.
View source ↗